XencorXNCR
XNCR
About: Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Employees: 250
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
157% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 35
3.67% more ownership
Funds ownership: 111.56% [Q1] → 115.23% (+3.67%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
6% less funds holding
Funds holding: 201 [Q1] → 188 (-13) [Q2]
23% less capital invested
Capital invested by funds: $836M [Q1] → $645M (-$191M) [Q2]
24% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 33
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
87%
upside
Avg. target
$23
183%
upside
High target
$27
237%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Leonid Timashev | 87%upside $15 | Outperform Maintained | 21 Aug 2025 |
Wells Fargo Eva Fortea Verdejo | 237%upside $27 | Overweight Maintained | 7 Aug 2025 |
Wedbush David Nierengarten | 225%upside $26 | Outperform Maintained | 7 Aug 2025 |
Financial journalist opinion
Based on 4 articles about XNCR published over the past 30 days
Negative
Zacks Investment Research
2 weeks ago
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $1.07 per share a year ago.
Positive
The Motley Fool
2 weeks ago
Xencor (XNCR) Q2 Revenue Jumps 82%
Xencor (XNCR) Q2 Revenue Jumps 82%
Neutral
Business Wire
2 weeks ago
Xencor Reports Second Quarter 2025 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2025 and provided recent business and clinical program updates. "Xencor is focused on execution of our clinical studies, evaluating four wholly owned XmAb® drug candidates in cancer and advanced autoimmune-driven diseases,” said Bassil.
Neutral
Business Wire
3 weeks ago
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies is a pioneering biochemist and cell biologist with more than 25 years of experience in biotechnology and drug development. He recently served as senior vice president of global research at Amgen Inc., whe.
Negative
Zacks Investment Research
3 months ago
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.11 per share a year ago.
Neutral
Business Wire
3 months ago
Xencor Reports First Quarter 2025 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a review of recent business and program updates. “Recently presented interim Phase 1 results support XmAb942 as a high potency investigational anti-TL1A antibody and an every 12-week subcutaneous dosing regimen during.
Negative
Zacks Investment Research
3 months ago
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
3 months ago
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results from its first-in-human study of XmAb942, a high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for patients with inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD). Interim results fro.
Positive
Zacks Investment Research
4 months ago
Xencor (XNCR) Upgraded to Buy: Here's Why
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Business Wire
5 months ago
Xencor Appoints Todd Simpson to Board of Directors
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023.
Charts implemented using Lightweight Charts™